# Rasagiline

## Rakinson 1mg

##### 

| TAH Drug Code      | [ORAK](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ORAK)                                                                                                                                                                                                                                                                                                                                                                                                              |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | ■Parkinson's disease, Initial monotherapy ■Parkinson's disease, To levodopa; Adjunct                                                                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | Monotherapy: 1 mg once daily Adjunctive therapy with levodopa: Initial: 0.5 mg once daily; may increase to 1 mg once daily based on response and tolerability                                                                                                                                                                                                                                                                                                                     |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Contraindications  | Concomitant use of cyclobenzaprine, dextromethorphan, methadone, propoxyphene, St John’s wort, or tramadol; concomitant use of meperidine or an MAO inhibitor (including selective MAO-B inhibitors) within 14 days of rasagiline                                                                                                                                                                                                                                                 |
| Adverse Effects    | ■Cardiovascular: Orthostatic hypotension (6% to 9%) ■Dermatologic: Rash (3% to 6% ) ■Endocrine metabolic: Weight loss (2% to 9% ) ■Gastrointestinal: Constipation (4% to 9% ), Indigestion (7% ), Nausea (10% to 12% ), Vomiting (4% to 7%), Xerostomia (2% to 6% ) ■Musculoskeletal: Arthralgia (6% to 11% ) ■Neurologic: Ataxia (3% to 6% ), Dyskinesia (18% ), Headache (8% to 14% ) ■Psychiatric: Depression (5% ) ■Other: Falling injury (5% ), Influenza-like illness (5% ) |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                      |

